Latest Breaking News On - Neurimmune ag - Page 1 : comparemela.com

Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered.

Christoph hockFabian bullerChief medical officerChief business officerReverse translational medicineNeurimmune ag